Study Using WST11 in Patients With Non-Resectable or Inoperable Cholangiocarcinoma

NCT ID: NCT00975039

Last Updated: 2016-04-18

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE2
• Total Enrollment: 8 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-09-30
• Study Completion Date: 2012-09-30

Brief Summary

The aim of this study is to evaluate the safety of Vascular Targeted Photodynamic therapy with WST11 in patients with non-resectable or inoperable biliary carcinoma.

Detailed Description

This is an open-label, prospective, multicentre, phase IIa study, evaluating a new therapeutic agent in the management of patients suffering from inoperable or non resectable biliary carcinoma. The patients will receive the dose of WST11 according to order of inclusion. The first 3 patients will receive 2.5 mg/kg. In the absence of toxicity, the following 9 patients will receive the dose of 5 mg/kg.

The patient is to receive anesthesia. WST11-mediated therapy will consist of the combination of single IV administration of WST11 at doses of 2.5mg/kg or 5mg/kg, using 753nm laser light at a fixed power of (150mW/cm) and light energy (200 J/cm) delivered through a diffusing fiber. The fiber is introduced in a transparent standard ERCP catheter and positioned under radioscopy in front of the lesion.

Conditions

Cholangiocarcinoma

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

WST11

Treatment with WST11-mediated VTP

Group Type: EXPERIMENTAL

WST11

Intervention Type: DRUG

WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.

Interventions

WST11

WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.

Intervention Type: DRUG

Other Intervention Names

WST11-mediated VTP

Eligibility Criteria

Inclusion Criteria

• Patient having signed the consent form to take part in the study
• Patient aged over 18 years, with no upper age limit
• Patient with histologically proven cholangiocarcinoma
• Patient with cholangiocarcinoma, inoperable or non resectable owing to extension, age or concomitant diseases
• Bilirubin level decrease of more than 50% after stent insertion compared to base level
• Patient with a WHO Performance Scale ≤ 2
• Patient in whom efficient drainage is performed by means of a plastic biliary stent endoscopically or radiologically
• Patient capable of completing the quality of life questionnaires
• Women of child-bearing potential must have a negative pregnancy test, and must thereafter prove to be using acceptable contraception (oral contraceptive pill, hormone patches, or IUD)

Exclusion Criteria

• Absence of consent to take part in the study
• Patient with operable biliary carcinoma
• Class ASA IV patients
• Patients presenting clinical and laboratory signs of biliary infection
• Absence of bilirubin decrease after stent insertion
• Patients with extrinsic biliary compression
• Patients already having received or currently receiving radiotherapy or chemotherapy for cholangiocarcinoma or needing to be treated during the first month of the follow-up
• Known metastatic lesions
• Patients having received immediate treatment by insertion of a metal stent
• Patients with porphyria or known hypersensitivity to porphyrins (contraindication to WST11)
• Patient receiving prohibited treatment at the time of inclusion in the study
• Pregnant or breast-feeding women
• Non-menopausal women not using effective contraception
• Majors under protection as per the French Public Health Code
• Persons not registered with or covered by a social security system
• Persons in an exclusion period relative to other biomedical study

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Steba Biotech S.A.

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Emmanuel Ben Soussan, MD

Role: PRINCIPAL_INVESTIGATOR

Clinique de l'Alma

Locations

Clinique de l'Alma

Paris, , France

Countries

France

Other Identifiers

CLIN904 CCM201

Identifier Type: -

Identifier Source: org_study_id